RxDoctor Payments Data

Brandi Royster, APRN

Family · Ashland, KYNPI 1841941143

Payments from drug & device makers

$1,791in general payments, 2019–2025

Across 135 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$442
  • Novo Nordisk$382
  • AbbVie$270
  • GSK$234
  • Lilly USA, LLC$159
  • Pfizer$107
  • plus $197 from 7 others

What the payments were for

  • Food & beverage$1,791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,791 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$78,215
Medicare patients
253
Services billed
3,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$156,251
XareltoRivaroxaban65$68,936
JardianceEmpagliflozin59$65,027
MounjaroTirzepatide54$62,240
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$37,378
TrulicityDulaglutide39$36,866
EliquisApixaban47$33,024
JanuviaSitagliptin Phosphate18$24,489
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$13,133
TradjentaLinagliptin18$11,840
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$7,815
Breo ElliptaFluticasone/Vilanterol11$6,620
MyrbetriqMirabegron14$6,320
Dexlansoprazole DrDexlansoprazole26$5,938
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$382$156,251131 claims
Lilly USA, LLCMounjaro, Trulicity$159$99,10693 claims
Johnson & JohnsonXarelto$442$68,93665 claims
GSKTrelegy Ellipta, Breo Ellipta$234$43,99847 claims
PfizerEliquis$107$33,02447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →